Cenduit buys patient compliance outfit to boost trial results

Site management specialist Cenduit has made its first acquisition, buying Patient Reminders and rolling out a service that allows sponsors to communicate directly with clinical trial subjects.

Through its Interactive Response Technology, Cenduit can now send patients personalized reminders of appointment times, dosage requirements and other essentials, helping to increase compliance and retention at trial sites, the company said. According to a recent study, patients who received text message reminders were 40% more likely to be retained in a trial, Cenduit said, and the company's new technology can integrate with mobile phones, calendars and email.

Neither company disclosed the financial terms of the deal.

CEO Jogin Desai said the buyout is Cenduit's first foray into expanding through M&A, but that despite the new reminder system's utility, technology is just one aspect of what's made his company successful.

"The other part is a thorough understanding--and response to patient and sponsor needs through continually evolving innovative products and services," Desai said in a statement. "Acquiring Patient Reminders is one more example of how Cenduit enables site efficiency and patient compliance for superior outcomes in current and future trials."

Earlier this year, Cenduit expanded its Durham, NC, headquarters and tripled the capacity of Basel, Switzerland, operation, responding to what Desai said is an increasing global demand for the company's patient recruitment and supply management services.

- read the announcement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.